[go: up one dir, main page]

DE69840509D1 - Apoptose-bezogene verbindungen und deren verwendung - Google Patents

Apoptose-bezogene verbindungen und deren verwendung

Info

Publication number
DE69840509D1
DE69840509D1 DE69840509T DE69840509T DE69840509D1 DE 69840509 D1 DE69840509 D1 DE 69840509D1 DE 69840509 T DE69840509 T DE 69840509T DE 69840509 T DE69840509 T DE 69840509T DE 69840509 D1 DE69840509 D1 DE 69840509D1
Authority
DE
Germany
Prior art keywords
acid sequence
apoptosis
compounds
ala leu
leu asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840509T
Other languages
English (en)
Inventor
Viveka Bjoerklund
Bertil Bjoerklund
Peter Bjoerklund
Marius Nap
Frans C Ramaekers
Bert Schutte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peviva AB
Original Assignee
Peviva AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703546A external-priority patent/SE9703546D0/xx
Application filed by Peviva AB filed Critical Peviva AB
Application granted granted Critical
Publication of DE69840509D1 publication Critical patent/DE69840509D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69840509T 1997-09-30 1998-09-25 Apoptose-bezogene verbindungen und deren verwendung Expired - Lifetime DE69840509D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6055697P 1997-09-30 1997-09-30
SE9703546A SE9703546D0 (sv) 1997-09-30 1997-09-30 Apoptosis-related compounds and their use
PCT/SE1998/001721 WO1999016789A1 (en) 1997-09-30 1998-09-25 Apoptosis-related compounds and their use

Publications (1)

Publication Number Publication Date
DE69840509D1 true DE69840509D1 (de) 2009-03-12

Family

ID=26663087

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840509T Expired - Lifetime DE69840509D1 (de) 1997-09-30 1998-09-25 Apoptose-bezogene verbindungen und deren verwendung

Country Status (9)

Country Link
US (3) US6296850B1 (de)
EP (1) EP1019438B1 (de)
JP (1) JP4372340B2 (de)
AT (1) ATE421531T1 (de)
AU (1) AU9291198A (de)
CA (1) CA2305681C (de)
DE (1) DE69840509D1 (de)
ES (1) ES2321351T3 (de)
WO (1) WO1999016789A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6162999A (en) 1998-09-24 2000-04-10 Promega Corporation Apoptosis marker antibodies and methods of use
WO2001051928A1 (en) * 2000-01-12 2001-07-19 Ventana Medical Systems, Inc. Method for quantitating a protein by image analysis
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003037361A2 (en) * 2001-11-02 2003-05-08 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US20040230903A1 (en) 2003-05-16 2004-11-18 Dethe Elza Method and system for enabling collaborative authoring of hierarchical documents with associated business logic
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
US20070243561A1 (en) * 2006-02-16 2007-10-18 Ben Geeraerts Prognostic markers in chronic lymphocytic leukemia
DE602007007595D1 (en) 2006-04-24 2010-08-19 Univ Wien Med Ten
WO2007136674A1 (en) 2006-05-19 2007-11-29 The Cleveland Clinic Foundation Detection and monitoring of liver damage
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
GB0911569D0 (en) 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
KR101061017B1 (ko) * 2009-10-23 2011-08-31 (주) 수파드엘릭사 암세포의 성장 및/또는 전이 억제용 약학 조성물
US9249231B2 (en) 2010-11-05 2016-02-02 Cell Signaling Technology, Inc. Motif-specific and context-independent antibodies that specifically bind to a cleaved caspase motif
EP2825886A4 (de) * 2012-03-14 2015-11-18 Stephen Marx Mittel und verfahren zur diagnose und therapie von erkrankungen
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6442412B2 (ja) 2013-03-15 2018-12-19 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
CN108265034A (zh) * 2016-12-30 2018-07-10 苏州和锐生物科技有限公司 杂交瘤细胞株及其产生的抗ck18-m30单克隆抗体与应用
JP7527559B2 (ja) 2020-06-05 2024-08-05 国立大学法人東京農工大学 フジツボ類キプリス幼生の付着誘起ペプチド及びその利用
JP2022128212A (ja) 2021-02-22 2022-09-01 シスメックス株式会社 モノクローナル抗体、サイトケラチン１８フラグメントの測定試薬、試薬キットおよび測定方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660994A (en) * 1986-11-10 1997-08-26 Progen Biotechnik Gmbh Method of detecting tissue-specific, insoluble cytoskeletal proteins
SE470273B (sv) * 1990-09-24 1993-12-20 Idl Immunodeveloplab Ab Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer

Also Published As

Publication number Publication date
ES2321351T3 (es) 2009-06-04
ATE421531T1 (de) 2009-02-15
US6716968B2 (en) 2004-04-06
WO1999016789A1 (en) 1999-04-08
JP2001518287A (ja) 2001-10-16
CA2305681C (en) 2013-01-08
US6706488B2 (en) 2004-03-16
JP4372340B2 (ja) 2009-11-25
EP1019438A1 (de) 2000-07-19
CA2305681A1 (en) 1999-04-08
EP1019438B1 (de) 2009-01-21
US20020081310A1 (en) 2002-06-27
US20020197657A1 (en) 2002-12-26
US6296850B1 (en) 2001-10-02
AU9291198A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
PT932678E (pt) Familia de genes que codificam peptidos relacionados com apoptose, peptidos por eles codificados e metodos para sua utilizacao
BR9507594A (pt) Processo para o tratamento de glomerulonefrite em um paciente necessitado deste tratamento artigo de fabricação anticorpo hibridoma 5g.1;1 molécula deácido nucleico proteina isolada polipeptideo isolado vetor de ácido nucleico célula hospedeira recombinante processo para produzir um polipeptideo de anticorpo c5 isolado anticorpo anti-c5 isolado processo para produzir uma proteina de anticorpo anti-c5 isolado molécula de ácido nucleico isolada processo para produzir um anticorpo anti-c5 anticorpo anti-c5 fragmento 5g46k fragmento 5g27k peptideo 5g325aa isolado peptideo 5g200aa isolado oligopeptideo isolado processo para induzir um animal a produzir um anti-c5 processo para identificar um anticorpo anti-c5 e processo para tratar um paciente necessitado de inibiçao complemetar
US7273850B2 (en) Paralytic peptide for use in neuromuscular therapy
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
ATE215830T1 (de) Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen
BR9810118A (pt) Anticorpo monoclonal ou policlonal ou ligando equivalente, uso do mesmo, peptìdeo, oligopeptìdeo, polipeptìdeo ou proteìna, uso dos mesmos, sequência de cdna, rna ou dna genÈmico, clone bacteriofago, plasmìdeo biologicamente funcional ou vetor viral, célula hospedeira, processos para a detecção de um autoanticorpo de ocorrência natural, e, de tratamento
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
EP1132402A4 (de) Peptidfragmente mit den zelltod verhindernden aktivität
Roos et al. Determination of the epitope of an inhibitory antibody to proliferating cell nuclear antigen
Heyermann et al. The heterogeneity of bovine IgG2—V. Differences in the primary structure of bovine IgG2 allotypes
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
Setlow et al. The complete covalent structure of protein B. The third major protein degraded during germination of Bacillus megaterium spores.
JPH03502446A (ja) 動物およびヒトのレクチン類の少なくとも一部分の配列を再現するアミノ酸配列，それを得る方法，およびその診断および治療への用途
Reboud et al. Identification of the proteins interacting with tRNA in rat liver small ribosomal subunits
DE69531167D1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen-karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
WO2003080662A1 (en) Protein kinase c modulators, their aminoacid and nucleotide sequences and uses thereof
SchenkmanSQl et al. Topology of Phage X Receptor Protein
Pischel et al. Further evidence for structural relatedness between murine MHC and thymus-leukemia antigens
Bamickel Modern Methods in Protein and Nucleic Acid Analysis
CA2087737A1 (en) Potential target for immunotherapy to prevent and cure rheumatoid arthritis and asthma in humans: cdna and protein structures for an intracellular activator of phospholipase a2 reconstructed from the antisense strand of human app gene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition